In this issue:
- Intravenous amino acids for protecting kidneys
- Frailty, multimorbidity and polypharmacy
- Effect of avenciguat on albuminuria in CKD
- SGLT-2 inhibitors and cause specific CV death in CKD
- Frailty aligns with survival in advanced CKD
- EOL planning in dialysis patients: limited nephrologist involvement
- Autoantibodies targeting nephrin in podocytopathies
- Questionnaire for evaluating referrals from primary to specialist nephrology care
- Restarting RAS inhibitors after discontinuation: kidney outcomes and mortality
- Impaired kidney function, cerebral small vessel disease and cognitive disorders
Please login below to download this issue (PDF)